Roche's Giredestrant combination meets phase III endpoints in advanced breast cancer
Importantly, the combination of giredestrant and everolimus was well tolerated
Importantly, the combination of giredestrant and everolimus was well tolerated
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem
This predictive technology empowers people with diabetes to take preventive action before complications arise
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
The lab will facilitate the development of herbal and natural-based solutions
Bayer Co.Lab AdVenture platform will accelerate biotech innovation through global investment networks
Pete Pharma will leverage FABRX’s extensive foundation of scientific validation to deliver a commercially viable, pharmacy-ready solution in the US
Subscribe To Our Newsletter & Stay Updated